Pattern of disease in recurrent cervical cancer associated with response to pembrolizumab.

Kathryn Miller,O.T. Filippova,Sara A. Hayes,Nadeem R. Abu Rustum,Carol Aghajanian,Vance Broach,Lora H. Ellenson,Elizabeth L. Jewell,Chrisann Kyi,Yulia Lakhman,Jennifer J. Mueller,Roisin OCearbhaill,Kay J. Park,Yukio Sonoda,Dmitriy Zamarin,Mario M. Leitao,Claire Frances Friedman

Pattern of disease in recurrent cervical cancer associated with response to pembrolizumab.

2020

Kathryn Miller
O.T. Filippova
Sara A. Hayes
Nadeem R. Abu Rustum
Carol Aghajanian
Vance Broach
Lora H. Ellenson
Elizabeth L. Jewell
Chrisann Kyi
Yulia Lakhman
Jennifer J. Mueller
Roisin OCearbhaill
Kay J. Park
Yukio Sonoda
Dmitriy Zamarin
Mario M. Leitao
Claire Frances Friedman

e18006Background: Pembrolizumab received accelerated FDA approval for treatment of metastatic or recurrent PD-L1 positive cervical cancer in 6/2018. Since then, the clinical characteristics of pati...

Keywords:

Oncology
Recurrent cervical cancer
Internal medicine
Pembrolizumab
Pathology
Disease
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations